 Patent Application Title |
Patent App Num. |
Date |
 Heterocyclic compound | 20130150364 | 20130613 |  The present inventors have investigated a compound having a PI3Kδ selective inhibitory action and/or an IL-2 production inhibitory action and/or a B cell proliferation inhibitory action (including an activation inhibitory action), and have found that the heterocyclic compound of the present invention has a PI3Kδ selective inhibitory action and/or and IL-2 production inhibitory action and/or a B cell proliferation inhibitory action (including an activation inhibitory action), thereby completing the present invention.
... | | Allergy testing device and method of testing for allergies | 20130138013 | 20130530 |  An allergy testing system comprises a skin test device having a grip portion for holding the device. One or more legs extend from the grip, and each leg is oriented to interact with a well containing a potential allergen. Each leg has a test head, and each test head has a plurality of elongated spike members. The elongated spike members have a sharp end configured to receive the potential allergen from a well and to puncture a patient's skin. In addition, each test head has at least one touch activator. The touch activator is longer than the plurality of elongated spike members, such that during an allergy test, the touch activator comes into contact with the skin prior to the elongated spike members, causing the touch... | | Lactic acid-fermented egg having reduced egg protein antigenicity through addition of sodium citrate, heating treatment, and lactic acid fermentation, and method for preparing same | 20130129863 | 20130523 |  The present invention relates to a lactic acid-fermented egg having reduced egg protein antigenicity and improved organoleptic quality through the addition of sodium citrate, heating treatment, and lactic acid bacteria fermentation, and more specifically, to a lactic acid-fermented egg having reduced egg protein antigenicity, which comprises a series of steps of adding to whole egg liquid a fixed amount of filtered water, sugar, and sodium citrate, heating treating and lactic acid-fermenting same, and a method for preparing same. The present invention reduces the antigenicity of ovomucoid and ovalbumin, which are allergy inducing factors existing inside an egg, has excellent solubility, and excellent organoleptic quality.
... | | Extensively hydrolyzed rice protein-based infant formula and use in feeding infants with food allergies | 20130115336 | 20130509 |  An infant formula was developed. This formula was specially designed for infants with history of allergy to cow's milk proteins, Which normally occurs in infants fed with infant formula. The invention represents a novelty, because in addition to its unique composition, the formula of the invention is more effective than the formulas commonly used to address the problem of protein allergy, and also it contains substances that support a proper physical and mental development of the infant.
... | | Linear ige peptide epitopes of hazelnut allergen cor a 1 and celery antigen api 1 | 20130101624 | 20130425 |  Linear polypeptide epitopes of hazelnut cor a 1 and celery api 1.0101 allergen of a sequence length of ten to fifteen amino acids for treatment and prevention of hazelnut or celery allergy are provided. Means and methods for diagnosing hazelnut or celery allergy, and for detecting hazelnut or celery allergens in a sample, are also provided.
... | Subscribe to updates on this page: Allergy RSS  | | Personal audio/visual system providing allergy awareness | 20130085345 | 20130404 | | A system provides a recommendation of food items to a user based on nutritional preferences of the user, using a head-mounted display device (HMDD) worn by the user. In a store, a forward-facing camera of the HMDD captures an image of a food item. The food item can be identified by the image, such as based on packaging of the food item. Nutritional parameters of the food item are compared to nutritional preferences of the user to determine whether the food item is recommended. The HMDD displays an augmented reality image to the user indicating whether the food item is recommended. If the food item is not recommended, a substitute food item can be identified. The nutritional preferences can indicate food allergies, preferences for low calorie... | | Formulations decreasing particle exhalation | 20130078282 | 20130328 | | Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.
... | | Methods of treating allergies with substantially phenol-free carriers | 20130064854 | 20130314 | | A method for treating a patient suffering from allergy by desensitizing the patient to an allergen component that includes orally, sublingually, or intranasally administering to the patient a therapeutically effective amount of an immunomodulating composition and successively repeating the administration at a selected interval with the therapeutically effective amount of each successive administration comprising an increasing amount of the allergen component. The composition includes an amount of the allergen component that is sufficient to impart an immune response and a pharmaceutically acceptable carrier that is at least substantially free of phenol. The successive repeating occurs a sufficient number of times to reduce patient sensitivity to the allergen component, and avoids or minimizes oral adverse effects. An immunomodulating product is also described.
... | | Allergen-specific induced tolerogenic dendritic cells for allergy therapy | 20130058976 | 20130307 | | Disclosed are allergen-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods.
... | | Polymorphic form of fexofenadine hydrochloride, intermediates and process for its preparation | 20130059886 | 20130307 | | The present invention relates to a novel polymorphic form of Fexofenadine hydrochloride, to a process for preparing it, to pharmaceutical compositions containing it, as well as its use. The invention also relates to intermediates useful for the preparation of Fexofenadine hydrochloride, antihistamine drug used in the treatment of allergy symptoms.
... | | Controlling allergy and asthma by activating human dcs via dectin-1 or toll-like receptor 2 (tlr2) | 20130052193 | 20130228 | | The present invention includes compositions and methods for enhancing Th1/Th17 cell responses and decreasing Th2 cell responses. In various embodiments the present invention describes activation of human dendritic cells and enhancement of antigen-specific T cell responses in a Dectin-1-expressing human dendritic cells comprising an anti-Dectin-1-specific antibody or fragment thereof fused with one or more antigens. TLR2 ligands may also be included to enhance the activation and for enhancement of T-cell responses. Further, the invention also includes methods based on the compositions described herein for the treatment of allergy, and asthma.
... | | Dermal filler composition | 20130053453 | 20130228 | | The present invention relates to a novel dermal filler composition and a method for preparing the same. Even though the composition of the present invention comprises, as a main component, only cross-linked dextran having the molecular weight of 30,000 to 100,000, the composition can rapidly augment a detective area of the skin and maintain softness to the touch even, the composition eliminates the necessity of a pretreatment, such as an allergy test, which might otherwise be required prior to injection, is inexpensive, and is not easily decomposed or absorbed in vivo, thereby stably maintaining the tissue-volume augmentation effects after injection over a long period of time.
... | | Fullerene derivative, method for producing the same, and allergen adsorbent using the same | 20130041185 | 20130214 | | Provided are a novel fullerene derivative which can adsorb quickly and efficiently an allergen which may cause a pollen allergy without releasing the allergen again, does not contain a metal or the like which may cause a harmful effect to a human body, and is easily applicable, impregnable, or chemically bondable onto surface of various materials; and a process for producing the same. The fullerene derivative is characterized in that a halogen group and many hydroxyl groups are bonded directly to a fullerene nucleus. In the case that the halogen group is chlorine, the fullerene derivative can be synthesized by a partial hydroxylation of a chlorinated fullerene or a partial chlorination of a hydroxylated fullerene.
... | Subscribe to updates on this page: Allergy RSS | | Method for the treatment and/or prevention of oral allergic symptions of the lips due to oral contact with a food allergen | 20130030009 | 20130131 | | A method of applying a topical preparation of at least one of a mast cell stabilizer, an antihistamine, and a leukotriene inhibitor is disclosed for prevention and/or treatment of oral allergy syndrome of the lips, including lip itchiness and/or swelling. For example, topical application of Cromolyn Sodium to the lips can be used to prevent and/or treat allergic reaction to consumption or other contact with raw fruits and/or raw vegetables. The topical administration can be performed by using applicator devices that apply at least one of a mast cell stabilizer and an antihistamine in the form of a liquid, or a gel, or a butter, or a wax-like solid, or a liposome suspension. Applicator devices can include at least one of: a roller, a brush, a... | | Nasal abrasion protector | 20130019878 | 20130124 | | A flexible nasal protection strip for use by cold and allergy suffers who, as part of their condition, must continually blow their nose with tissues. The protection strip consists of a die-cut strip of medical grade clear, colored or imprinted plastic with adhesive on one side that is temporarily protected by a peelable film. The protection strip is flexible enough to conform to the nose but not interfere with breathing. The unique design protects the exterior sidewalls and tip of the nose from the habitual abrasion caused by excessive tissue rubbing. The protection strip could also be impregnated with a variety of compounds including: compressed iron oxides and salts to produce chemically-based heat protecting the nose from damage in extreme cold and chemicals or metals offering... |
| Treatment and/or prevention of oral allergic symptoms caused by oral contact with fruits and/or vegetables | 20130017247 | 20130117 | | Treatment or prevention of oral allergy syndrome, or other allergy-related oral inflammatory processes using a topical preparation of at least one of a mast cell stabilizer and an antihistamine is disclosed. For example, the topical administration of Cromolyn Sodium prior to ingestion of raw fruits and raw vegetables may be used to prevent oral allergy symptoms. The topical administration can be performed by use of a solution, a powder, an aerosol, a tablet, a chewable tablet, a gel, a melting strip, a mouth rinse, a mouth swab, or a piece of candy, and may be combined with carrier molecules and/or mucoadhesive molecules to enhance efficacy.
... | | Diagnosis support system, method and program | 20130006669 | 20130103 | | A constitution information obtainment unit obtains constitution information about a patient to be diagnosed including at least one of genetic information and allergy information about the patient. A comparison constitution information obtainment unit obtains, as comparison constitution information, constitution information about plural patients to be compared. A similar constitution information extraction unit calculates, with respect to the comparison constitution information about the plural patients to be compared, degrees of similarity to the constitution information about the patient to be diagnosed, respectively, and extracts, as similar constitution information, the comparison constitution information the calculated degree of similarity of which satisfies a predetermined threshold condition. A reference information extraction unit extracts, with respect to each extracted similar constitution information, a drug administered to the patient corresponding to the... | | Administration of plant expressed oral tolerance agents | 20130007926 | 20130103 | | Protein replacement therapy for patients with hemophilia or other inherited protein deficiencies is often complicated by pathogenic antibody responses, including antibodies that neutralize the therapeutic protein or that predispose to potentially life-threatening anaphylactic reactions by formation of IgE. Using murine hemophilia B as a model, we have developed a prophylactic protocol against such responses that is non-invasive and does not include immune suppression or genetic manipulation of the patient's cells. Oral delivery of coagulation factor IX (F. IX) expressed in chloroplasts, bioencapsulated in plant cells, effectively blocked formation of inhibitory antibodies in protein replacement therapy. Inhibitor titers were mostly undetectable and up to 100-fold lower in treated mice when compared to controls. Moreover, this treatment eliminated fatal anaphylactic reactions that occurred after 4 to 6 exposures... | | Allergy inhibitor | 20120329752 | 20121227 | | The present invention relates to a substance for inhibiting allergic diseases. Amorphous paramylon of the present invention is an allergy inhibitor comprising amorphous paramylon which is obtained by amorphosizing crystalline paramylon derived from Euglena, and has a relative crystallinity of 20% or lower to the crystallinity of crystalline paramylon, determined by an X-ray diffractometry. This allergy inhibitor enables efficacious inhibition of allergic diseases such as atopic dermatitis, pollinosis, and the like.
... | | Epithelial cell-cell adhesion enhancer, and ameliorating, therapeutic or prophylactic agent for allergic diseases using same | 20120315342 | 20121213 | | Disclosed is a composition containing a specific oligosaccharide and a bivalent metal cation, which exhibits an effect on the amelioration, treatment or prevention of allergy or topical inflammatory reactions in an extremely safe and effective manner compared to synthetic oral steroid medicines in spite of a fact that the composition contains components that are generally familiar as a food or an ion occurring in living bodies and have no toxicity against living bodies when used at physiological concentrations. Specifically disclosed is a cell-cell adhesion enhancer in epithelial cells, which comprises 1-kestose and/or nystose and a bivalent metal cation as active ingredients. The enhancer can prevent the disruption of an epithelial cell-cell tight junction protein that causes the invasion of an allergen into the body, can repair... | | Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases | 20120316197 | 20121213 | | This invention relates to a compound with EP4 antagonistic activity, or a pharmaceutically acceptable salt with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a pharmaceutical composition for the treatment of immune disease or allergy which comprises a therapeutically effective amount of a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof. Further this invention relates to a method for the treatment of immune disease or allergy in an... | | Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis | 20120294849 | 20121122 | | The present invention provides a method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis, or of reducing, inhibiting or treating allergy like symptoms. The methods use compositions comprising chlorite, chloride, chlorate and/or sulfate ions.
... | | Tolerogenic synthetic nanocarriers for allergy therapy | 20120294888 | 20121122 | | Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.
... | | Automated allergy alerts | 20120286959 | 20121115 | | Devices, systems, and methods are disclosed which relate to utilizing a wireless communication device which receives allergy information from network nodes. The wireless communication device contains an allergy profile for the user. When the wireless communication device receives allergy information this allergy profile is referenced to determine if any allergens near the user may cause a problem for the user. If allergens exist to which the user is allergic, a visual, aural, and/or tactile alert is output on the wireless communication device.
... | | Use of n-phenyl-2-pyrimidineamine derivatives against mast cell-based diseases like allergic disorders | 20120277246 | 20121101 | | in which the symbols and substituents have the meaning as given herein in free form or in pharmaceutically acceptable salt form in the manufacture of a pharmaceutical composition for the treatment of allergic rhinitis, allergic dermatitis, drug allergy or food allergy, angioedema, urticaria, sudden infant death syndrome, bronchopulmonary aspergillosis, multiple sclerosis or mastocytosis;
... | | Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions | 20120277279 | 20121101 | | a process for their preparation, to pharmaceutical compositions comprising the compounds and the preparation of said compositions, to intermediates and to use of the compounds for the manufacture of a medicament for therapeutic treatment, particularly for the treatment of inflammation, allergy and/or auto-immune conditions.
... | | Method for the pasteurization of wine on a production basis in the winery | 20120269946 | 20121025 | | Attaining biological stability in wine has been a problem for winemakers for centuries. The main methods for preventing microbes from destroying wine have been the addition of chemicals such as sulphur dioxide and potassium sorbate and ultra filtration. These methods are less than satisfactory. Chemicals can only be used to a certain level before they affect the taste of the wine or cause allergy reactions in the drinker. Ultra filtration will remove the microbes but it also removes taste and body from the wine. Previous attempts at pasteurization of wine have been marginally successful because of the subsequent spoilage of the wine in less than optimum winery storage and less than total kill of the microbes. I have devised a method to eliminate these problems and... | | Medicinal cream made using hydrocortisone acetate and a process to make the same | 20120270835 | 20121025 | | The present invention relates to a composition for treating skin inflammation, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, and a corticosteroid. It discloses a composition for treating skin inflammation, along with skin rejuvenation containing a) a biopolymer in the form of chitosan, b) an active pharmaceutical ingredient (API) composition in the form of hydrocortisone acetate, used in treating skin inflammation c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants and d) water. The active ingredients, namely chitosan, and a corticosteroid in the form of hydrocortisone acetate, are incorporated in cream base for use in treating skin inflammation due to allergy & itching &... | | home or point-of-care allergy testing | 20120264230 | 20121018 | | An allergy testing method based on a highly sensitive testing of a small blood sample is provided. The method includes collecting a blood sample from a subject, the blood sample being limited to a volume taken from a skin-prick; and, testing serum from the blood sample without dilution for an allergic response of the subject to one or more allergens, the testing having a high detection sensitivity ranging from about 10̂-9 g/ml to about 10̂-12 g/ml.
... | | Antigen detection system and methods of use | 20120264232 | 20121018 | | A system and method for testing for the presence of antigens in food stuffs permits a user to test food products for the presence of antigens for a given food allergy that the user may have. The system comprises two main components, a base station and a test well. The user places a sample of food into the test well. A macerator homogenizes the food in the test well. Antibodies to a particular antigen are bound to an antigen detector in the test well. The base station includes a cartridge dock which powers the macerator and the antigen detector. Antigen-antibody binding provides a change detectable by the detector, which signals the base station of the presence of a threshold degree of antigen-antibody binding and alerts the... | | Bifidobacterium for dust mite allergy | 20110014156 | 20110120 | | A composition comprising Bifidobacterium breve for use in improving lung function in human subjects suffering from dust mite allergy.
... | | Therapeutic and diagnostic uses of antibody specificity profiles | 20100330110 | 20101230 | | This invention provides a method for determining the antibody specificity profile in an individual. This specificity profile reveals the individual's immune response to multiple antigens and/or epitopes of autoantigens, allergens, graft antigens, etc. The antibody specificity profile is determined through the binding of patient samples comprising antibodies to the arrays. The array can comprises antigens and epitopes. The invention also provides the means and methods for determining antigen or epitope specificity profiles that can be used in the development of either generic and individualized diagnosis and treatment for immune related diseases, including autoimmune disease, allergy and graft rejection.
... | | Novel traf family proteins | 20100324267 | 20101223 | | In accordance with the present invention, there are provided novel TRAF-Protein-Binding-Domain polypeptides (TPBDs). The invention also provides nucleic acid molecules encoding TPBDs, vectors containing these nucleic acid molecules and host cells containing the vectors. The invention also provides antibodies that can specifically bind to invention TPBDs. Such TPBDs and/or anti-TPBD antibodies are useful for discovery of drugs that suppress autoimmunity, inflammation, allergy, allograph rejection, sepsis, and other diseases.
... | | Pyridosulfonamide derivatives as p13 kinase inhibitors | 20100311736 | 20101209 | | Invented is a method of inhibiting the activity/function of PI3 kinases using pyridosulfonamide derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of pyridosulfonamide derivatives.
... | | Novel wheat allergens | 20100305049 | 20101202 | | The present invention relates to the field of IgE-mediated allergy, particularly occupational asthma such as bakers asthma. More specifically the invention relates to the identification of a novel wheat allergen and the use thereof in therapy and diagnosis of IgE-mediated allergy. Furthermore the present invention provides the use of known peptides and proteins in therapy and diagnosis. The invention also relates to methods for diagnosis and treatment of IgE-mediated allergy in mammals.
... | | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity | 20100303846 | 20101202 | | The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.
... | | Allergens and allergoids from bee venom | 20100297188 | 20101125 | | The present invention concerns the preparation of purified allergens and allergoids, both derived from whole bee venom, for the desensitisation (immunotherapy) of subjects affected by a specific allergy. In particular, the present invention concerns a preparation for immunotherapy based on purified bee venom, characterised in that said bee venom is essentially mellitin-free. In addition, the preparation of a monomeric allergoid obtainable through the carbamylation or thiocarbamylation reaction of said mellitin-free bee venom, is described. Said allergoid, being characterised by reduced IgE-binding activity, may be a safer and more effective candidate for specific immunotherapy.
... | | Therapeutic uses of cannabigerol | 20100292345 | 20101118 | | The present invention relates to the use of the cannabinoid cannabigerol (CBG) in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from concurrent agonism of the CBi and the CB2 cannabinoid receptors. Such diseases or conditions to be treated are taken from the group: pain, neurodegenerative disease, ischemic disease, brain injury or damage, acquired brain injury, age related inflammatory or autoimmune disease, cachexia, nausea and vomiting, glaucoma, movement disorders, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn's disease, systemic lupus erythematosus, diabetes, cancer, osteoporosis, renal ischemia and nephritis.
... | | Uses of 2-[piperidinyl] methyl-2, 3-dihydroimidazo [1,2-c] quinazolin-5 (6h)-one for providing an analgesic effect, anti-allergic effect and histamine h1 receptor antagonism effect | 20100292257 | 20101118 | | The present invention discloses new uses of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one in providing an analgesic effect in a patient, treating passive cutaneous anaphylaxis in a patient, and in eliciting a histamine H1 receptor antagonism effect in a patient to treat a disease or disorder, such as allergy.
... | | Allergy vaccine composition for mucosal administration | 20100291155 | 20101118 | | The present invention relates to an allergy vaccine composition for mucosal administration comprising a cysteine protease allergen in a reduced active state or in an oxidised inactive state, The inventions further relates to an adjuvant system for use in a vaccine for mucosal administration comprising a cysteine protease.
... | | Antisense oligonucleotides for treating atopic diseases and neoplastic cell proliferation | 20100286239 | 20101111 | | The present invention relates to the use of antisense oligonucleotides directed against specific nucleic acid sequences coding for receptors, alone or in combination, in order to inhibit the inflammatory reaction that is present in asthma, atopy or hypereosinophilia and to inhibit neoplastic cell proliferation. The antisense oligonucleotides of the present invention are used for treating and/or preventing asthma, allergy, hypereosinophilia, general inflammation or cancer. The oligonucleotides of the present invention are more specifically directed against nucleic acid sequences coding for a CCR3 receptor, a common sub-unit of IL-4 and IL-13 receptors, or a common sub-unit of IL-3, IL-5 and GM-CSF receptors.
... | | Use of a l. casei strain for the preparation of a composition for inhibiting mast cell activation | 20100284973 | 20101111 | | The present invention pertains to the field of prevention and treatment of chronic or acute diseases involving mast cells, such as allergy and some autoimmune diseases. More precisely, the present invention concerns the use of probiotics containing a L. casei strain and/or a B. breve strain for inhibiting mast cell activation. The present invention relates also to screening processes for identifying bacterial strains which can be used for preparing said probiotics.
... | | Read-out method and apparatus | 20100284583 | 20101111 | | A read-out method for a diagnostic point-of-care assay device, the device including a read-out substrate having at least one response area capable of producing a coloured indication of a response, the response area including a marker at least one marker whose colour changes in response to binding of an analyte thereto and which is used for indication of response. The method includes registering an image of the response area; calculating a colour saturation value S for the image using at least two distinct wavelengths; using the S-value for determining a result of the assay. A read-out system (10) for an allergy point-of-care assay device is described. The system includes an illumination device (12; 21, 22) capable of delivering at least two different wavelengths of light; a... | | Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations | 20100280059 | 20101104 | | The invention provides oral formulations for the treatment of cold and allergy symptoms. Each formulation combines an antihistamine, an antitussive, and/or a decongestant into one extended release composition. The invention further provides for methods of making and using such formulations, as well as for methods for preventing abuse or extraction of a single drug present in an oral extended release composition comprising two or more of an antihistamine, antitussive, and/or decongestant.
... | | Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations | 20100278915 | 20101104 | | The invention provides oral formulations for the treatment of cold and allergy symptoms. Each formulation combines an antihistamine, an antitussive, and/or a decongestant into one extended release composition. The invention further provides for methods of making and using such formulations, as well as for methods for preventing abuse or extraction of a single drug present in an oral extended release composition comprising two or more of an antihistamine, antitussive, and/or decongestant.
... | | Device and method for the diagnosis of gastrointestinal allergy | 20100278753 | 20101104 | | A method and device for the diagnosis of gastrointestinal allergy. The method and the device expose a surface to at least one antigen at a fixed depth. The device includes an application point each having an antigen allowing for the application of the antigen to the surface at a fixed depth. The device may include multiple applications points each with an antigen for simultaneously applying the antigens to the surface.
... | | N-acylic aminoacid derivatives, method for the production thereof, pharmacological composition and the use in the form anti-allergic, anti-inflammatory and hypolipidemic agents | 20100267962 | 20101021 | | or pharmaceutically acceptable salts thereof, to novel processes for preparing the same, to use thereof as anti-allergic, anti-anaphylactic, anti-inflammatory and hypolipidemic agents as well as to a pharmaceutical composition comprising the indicated compounds in an efficient amount and to a method for treating allergic and inflammatory diseases and lipid metabolism disorders: bronchial asthma, allergic rhinitis, pollinoses, seasonal and year-round rhinitis, allergic pneumonitis, atopic dermatitis, psoriasis, urticaria, allergic (including anaphylactic) reactions to insect stings and medicaments, cold allergy, allergic conjunctivitis, atherosclerosis, obesity, ischemic heart and cerebral disease, myocardial infarction and stroke.
... | | Avenanthramide-containing compositions | 20100267662 | 20101021 | | Methods and compositions for treating or preventing a skin condition, an inflammation, an irritation or an allergy associated with an ectoparasitic infection or infestation on an animal. The methods involve applying to the skin of the animal a pharmaceutical composition that contains a therapeutically effective amount of one or more than one avenanthramide, an optional ecto and/or endo-parasiticidal agent, and a pharmaceutically acceptable diluent or carrier
... | | Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors | 20100266604 | 20101021 | | This disclosure concerns compositions and methods for immunoenhancement and/or immunosuppression. In certain embodiments, the disclosure concerns methods of using a TAM receptor inhibitor for immunoenhancement, for example as a vaccine adjuvant, for the treatment of sepsis, or for treating an immunocompromised subject. Also disclosed are methods of screening for immunoenhancing agents. In other embodiments, the disclosure concerns methods of using a TAM receptor agonist for immunosuppression, for example as a treatment for an autoimmune disorder, for the treatment of an allergy, or for treating graft-versus-host disease in a subject. Also disclosed are methods of screening for immunosuppressive agents.
... | | Methods and kits for screening transplant recipients and candidates | 20100261203 | 20101014 | | Methods and kits are provided for determining of immunoglobulin isotypes and subclasses in a subject. In general the subject is a human who is a transplant candidate recipient or recipient, has allergies, or has an autoimmune disease. The method involves analyzing a sample of a body fluid of a transplant candidate or recipient, allergy patient or autoimmune disease sufferer and correlating the relative amounts of each immunoglobulin isotype and subtype, such that the distribution of isotypes and subtypes is an indication of success of the transplant in the candidate and recipient or the prognosis of the autoimmune disease.
... | | Peptide for vaccine | 20100260805 | 20101014 | | The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.
... | | Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties | 20100260788 | 20101014 | | Immunostimulatory oligoribonucleotides (ORN) featuring 5′-triphosphates and various 5′-triphosphate analogs are provided. Also provided are physiologically acceptable salts of the immunostimulatory ORN and pharmaceutical compositions containing the immunostimulatory ORN of the invention. ORN of the invention are useful as adjuvants and can be combined with an antigen to promote an antigen-specific immune response. ORN of the invention are also particularly useful for promoting a Th1-type immune response. Also provided are methods of use of the compounds and pharmaceutical compositions of the invention to enhance an immune response in a subject, as well to treat a number of conditions including cancer, infection, allergy, and asthma, and to vaccinate a subject against an antigen.
... | | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor | 20100256373 | 20101007 | | Benzoimidazol-2-yl pyrimidines and pyrazines, pharmaceutical compositions and methods for H4 receptor activity modulation and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritis.
... | | Tosylate salt of trans-n-isobutyl-3-fluoro-3- [3-fluoro-4-(pyrrolidin-1-yl-methyl)-phenyl] cyclobut anecarboxamide | 20100256213 | 20101007 | | to solvates (e.g., hydrates) thereof, to polymorphs thereof, to pharmaceutical compositions thereof and to a method of treating depression, mood disorders, schizophrenia, anxiety disorders, cognitive disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper- and hypo-motility and acidic secretion of the gastro-intestinal tract comprising administering a therapeutically effective amount thereof.
... | | Oxypiperidine derivatives and methods of use thereof | 20100249098 | 20100930 | | The present invention relates to novel Oxypiperidine Derivatives, pharmaceutical compositions comprising the Oxypiperidine Derivatives and the use of the Oxypiperidine Derivatives for treating or preventing treating allergy, an allergy-induced airway response, congestion, hypotension, a cardiovascular disease, a gastrointestinal disorder, obesity, a sleep disorder, pain, diabetes, a diabetic complication, impaired glucose tolerance, impaired fasting glucose or a central nervous system (CNS) disorder.
... | | Method, apparatus and computer program product for displaying and permitting revision of a potential interaction | 20100241453 | 20100923 | | A method, apparatus and computer program product are provided for displaying and permitting revision of a potential interaction with a medication under consideration for prescription to a patient. Initially, one or more potential interactions may be identified between a medication and one or more of a different medication, an allergy or a patient condition. The potential interactions may then be displayed with an indication of the type of potential interaction and the severity of the potential interaction. An input mechanism may be provided that is associated with the display of each potential interaction and that is configured to receive user input indicative of a change in one or more of the different medication, the allergy or the patient condition. Based upon this change, the potential interactions... | | External preparation for percutaneous administration containing nonsteroidal anti-inflammatory analgesic | 20100240758 | 20100923 | | An external preparation for percutaneous administration which contains a light-sensitive nonsteroidal anti-inflammatory analgesic and a UVA-shielding agent which inhibits the analgesic to cause light toxicity and a light allergy. This external preparation for percutaneous administration, which contains a nonsteroidal anti-inflammatory analgesic, can be prevented, with higher certainty, from causing the hypersensitivity to light attributable to light toxicity and a light allergy.
... | | Ophthalmic formulations of ketotifen and methods of use | 20100240624 | 20100923 | | The present invention provides topical formulations of ketotifen that provide a comfortable formulation when instilled in the eye and are effective in the treatment and prevention of ocular allergy, particularly allergic conjunctivitis. The invention further provides methods of treating and preventing ocular allergy by in a subject in need of such treatment by topical application of the ketotifen formulations of the invention to the eye of a subject in need thereof.
... | | Vaccine peptide combinations against cat allergy | 20100239599 | 20100923 | | The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides.
... | | Novel compounds | 20100234441 | 20100916 | | a process for their preparation, to pharmaceutical compositions comprising the compounds and the preparation of said compositions, to intermediates and to use of the compounds for the manufacture of a medicament for therapeutic treatment, particularly for the treatment of inflammation, allergy and/or autoimmune conditions.
... | | Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor | 20090325927 | 20091231 | | Benzofuro- and benzothienopyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.
... | | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | 20090325928 | 20091231 | | and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
... | | Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions | 20090324507 | 20091231 | | RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
... | | Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient | 20090318703 | 20091224 | | wherein R1 is —COOH, —COOR6, etc.; A is a single bond, alkylene, etc.; R2 is alkyl, alkoxy, etc.; B is a carbocyclic ring or a heterocyclic ring; Q is alkylnene-Cyc2, etc.; D is a linking chain; and R3 is alkyl, a carbocyclic ring or a heterocyclic ring, or a non-toxic salt thereof. The compound of formula (I) binds to PGE2 receptor, especially subtypes EP3 and/or EP4 and show the antagonizing activity, are useful for the prevention and/or treatment of diseases induced pain, itch, urticaria, allergy, urinary frequency, urinary disturbance, Alzheimer's disease, cancer, dysmenorrhea, endometriosis, etc.
... | | Therapeutic peptide compositions and methods of making and using same | 20090311236 | 20091217 | | Therapeutic compositions include peptide formulations having a mixture of serum, albumin, casein, peptone, pacreatin, and sodium hydroxide. The peptide compositions do not include nucleic acid or any derivatives thereof. The peptide compositions have beneficial therapeutic properties to boost human immune system and to treat various ailments including malaria, allergy and inflammation. The peptide compositions, one having a molecular weight greater than 10 kDa and having amino acid residues in a range of 27 and 315, and the other having a molecular weight equal to or less than 10 kDa and amino acid residues in a range of 27 and 54, their structures and therapeutic properties are discussed.
... | | Thiazolidinedione derivatives as p13 kinase inhibitors | 20090306074 | 20091210 | | Invented is a method of inhibiting the activity/function of PI3 kinases using thiazolidinedione derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of thiazolidinedione derivatives.
... | | Immunomodulatory agents for treatment of inflammatory diseases | 20090305985 | 20091210 | | The present invention provides methods and compositions suitable for treating inflammatory disorders such as allergy, asthma, artherosclerosis, autoimmune disease, infection, injury, meningitis, psoriasis, and transplant rejection. In particular, the present invention provides methods and compositions comprising human S100A8 and/or S100A9 for reducing inflammation.
... | | Method for preparing hypoallergenic derivatives of fruit and/or vegetable pieces | 20090304883 | 20091210 | | The object of the present invention is a novel fruit and vegetable transformation process for the production of hypoallergenic industrial derivatives in pieces (cubes, slices, segments etc.), intended mainly for individuals with OAS (Oral Allergy Syndrome) following the consumption of fresh products and/or the traditional industrial derivatives thereof, but also for general consumption in order to prevent sensitisation in atopic patients. In a second aspect, the present invention also relates to products that can be obtained by means of said process.
... | | Compositions and methods for the diagnosis and treatment of immune disorders | 20090304703 | 20091210 | | In this regard, the invention provides methods for the identification and therapeutic use of compounds for treatments of immune disorders, especially TH cell subpopulation-related disorders and including TH2 and TH2-like disorders (i.e., disorders associated with a TH2 or TH2-like mediated immune response) such as atopic conditions (e.g., allergy and asthma). Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders and for monitoring the efficacy of compounds used in clinical trials.
... | | Methods for the treatment and prevention of infection using anti-selectin agents | 20090304681 | 20091210 | | Methods for the treatment and prevention of pulmonary infections are disclosed, in particular, methods comprising the administration of one or more anti-selectin agents to a patient diagnosed with a pulmonary infection. Anti-selectin agents that inhibit leukocyte recruitment to the lungs have been found to be beneficial for the treatment of lung infections, including infections associated with chronic bronchitis, chronic obstructive pulmonary disease (COPD), pneumonia, pneumonitis, acute respiratory distress syndrome (ARDS), severe acute respiratory syndrome (SARS), sarcoidosis, cystic fibrosis (CF), emphysema, asthma, smoker's cough, allergy, allergic rhinitis, sinusitis and pulmonary fibrosis.
... | | Method of genetically altering and producing allergy free cats | 20090298168 | 20091203 | | A transgenic cat with a phenotype characterized by the substantial absence of the major cat allergen, Fel d I. The phenotype is conferred in the transgenic cat by disrupting the coding sequence of the target gene with a specialized construct. The phenotype of the transgenic cat is transmissible to its offspring.
... | | Use of a liquid allergy vaccine formulation for oromucosal administration | 20090297564 | 20091203 | | The present invention relates to the use of an allergen for the manufacture of a liquid vaccine formulation for preventing or treating allergy in a subject by oromucosal administration in a dosage regimen comprising no up-dosing.
... | | Inhibition of calpain reduces allergic inflammation | 20090297510 | 20091203 | | The present invention provides for the use of a calpain inhibitor for the treatment of allergy diseases, inflammatory diseases and autoimmune diseases. In particular, it has been found that inhibition of calpain within mast cells decreases the release of chemical mediators into the surrounding environment, resulting in a decreased local inflammatory response. The present invention also provides for a method of decreasing IgE-dependent mast cell degranulation, mast cell mediator release and cytokine production in mast cells, comprising the step of administering to the mast cells an effective amount of a calpain inhibitor.
... | | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists | 20090286830 | 20091119 | | and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders using said compounds, alone or in combination with other agents.
... | | Allergenic proteins of natural rubber latex, their production and use in assays | 20090285859 | 20091119 | | This invention relates to allergenic proteins of natural rubber latex in substantially purified form, their production and their use, together with monoclonal antibodies developed against those allergenic proteins, in assays for the qualitative and quantitative determination of the levels of the allergenic proteins in natural rubber latex or in products made from latex. Assays for identifying and/or quantitating antibodies in blood or blood products that mediate the occurrence of an allergic reaction induced by natural rubber latex are also provided, together with in vivo and in vitro diagnostic tests for detecting hypersensitivity to natural rubber latex and which involve use of the aforesaid allergenic proteins. The invention also provides for the use of the aforesaid allergens as de-sensitising agents in the treatment of latex protein allergy.... | | Prevention of allergy in children | 20090285858 | 20091119 | | The present invention relates to a use of bacterial superantigens in the manufacture of a pharmaceutical composition for mucous membrane administration for the prevention of inflammatory disorders in newborn infants, such pharmaceutical compositions, as well as method for prevention of inflammatory disorders.
... | | Surface acoustic wave immunosensor for diagnosing allergy disease and method for diagnosing allergy disease using the same | 20090280509 | 20091112 | | A surface acoustic wave (SAW) immunosensor for diagnosing allergy disease includes one or more SAW devices on each of which allergens derived from one allergy-causing substance are fixed and an allergen derived from another allergy-causing substance is not included, that is, allergens derived from different allergy-causing substances being fixed on different SAW devices; and a signal detector which detects an output signal from the SAW device. Also a method for diagnosing allergy disease is capable of measuring levels of allergen-specific IgE and total IgE in blood or another sample taken from a subject of diagnosis using a SAW immunosensor, the allergens being derived from various allergy-causing substances, thereby capable of effectively diagnosing allergy disease for various allergy-causing substances.
... | | Interferon alpha and c-phycocyanin for the treatment of autoimmune diseases, allergy and cancer | 20090280087 | 20091112 | | The present invention consists of the combination of Interferon alpha and C-Phycocyanin (IFN-α/C-Phyco) for obtaining a pharmaceutical preparation for autoimmune disease, allergy and cancer treatments. The anti-inflammatory, immunomodulator, antioxidant, anti-viral, anti-proliferative and anti-tumoral effects, associated to the regulatory T cell inducer effect demonstrated in this invention is the rationale for the use of the IFN-α/C-Phyco combination in these diseases.
... | | Surface acoustic wave immunosensor for diagnosing allergy disease and method for diagnosing allergy disease using the same | 20090280509 | 20091112 | | A surface acoustic wave (SAW) immunosensor for diagnosing allergy disease includes one or more SAW devices on each of which allergens derived from one allergy-causing substance are fixed and an allergen derived from another allergy-causing substance is not included, that is, allergens derived from different allergy-causing substances being fixed on different SAW devices; and a signal detector which detects an output signal from the SAW device. Also a method for diagnosing allergy disease is capable of measuring levels of allergen-specific IgE and total IgE in blood or another sample taken from a subject of diagnosis using a SAW immunosensor, the allergens being derived from various allergy-causing substances, thereby capable of effectively diagnosing allergy disease for various allergy-causing substances.
... | | Interferon alpha and c-phycocyanin for the treatment of autoimmune diseases, allergy and cancer | 20090280087 | 20091112 | | The present invention consists of the combination of Interferon alpha and C-Phycocyanin (IFN-α/C-Phyco) for obtaining a pharmaceutical preparation for autoimmune disease, allergy and cancer treatments. The anti-inflammatory, immunomodulator, antioxidant, anti-viral, anti-proliferative and anti-tumoral effects, associated to the regulatory T cell inducer effect demonstrated in this invention is the rationale for the use of the IFN-α/C-Phyco combination in these diseases.
... | | Rnai-mediated inhibition of histamine receptor h1-related conditions | 20090274631 | 20091105 | | RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
... | | Rnai-mediated inhibition of histamine receptor h1-related conditions | 20090274631 | 20091105 | | RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
... | | Foot-bath agent of chinese herbal medicine for regulating blood pressure and improving sleep quality | 20090269423 | 20091029 | | The present invention relates to a foot-bath agent of Chinese herbal medicine for regulating blood pressure and improving sleep quality, and the components of the formula thereof are as follows: fructus leonuri 20-25%, semen ziziphi spinosae 15-20%, calcined magnetitum 17-22%, spica prunellae 15-20%, ligusticum chuanxiong hort 18-23%, borneolum 0.7-1.2%; provided that, after the final product is prepared using the above raw materials and the blending ratios thereof, the sum of all components should be 100% by weight. The foot-bath agent prepared has advantages including an efficacious and healthy method thereof being highly consistent with healthy living habits of people, an effective regulation of blood pressure and improvement of sleep quality, no allergy and less side effects to human body, and thus obviously is worthy to be... | | Foot-bath agent of chinese herbal medicine for regulating blood pressure and improving sleep quality | 20090269423 | 20091029 | | The present invention relates to a foot-bath agent of Chinese herbal medicine for regulating blood pressure and improving sleep quality, and the components of the formula thereof are as follows: fructus leonuri 20-25%, semen ziziphi spinosae 15-20%, calcined magnetitum 17-22%, spica prunellae 15-20%, ligusticum chuanxiong hort 18-23%, borneolum 0.7-1.2%; provided that, after the final product is prepared using the above raw materials and the blending ratios thereof, the sum of all components should be 100% by weight. The foot-bath agent prepared has advantages including an efficacious and healthy method thereof being highly consistent with healthy living habits of people, an effective regulation of blood pressure and improvement of sleep quality, no allergy and less side effects to human body, and thus obviously is worthy to be... | | Short interference ribonucleic acids for treating allergic diseases | 20090264503 | 20091022 | | Provided herein are compounds, methods and compositions for treating allergic diseases. In particular, an isolated double stranded short interfering ribonucleic acid (siRNA) with a ribonucleotide sequence complementary to at least a portion of a target gene RNA such as an airway inflammation related-gene RNA, thereby resulting in the cleavage of the expressed target gene RNA via RNA interference mechanism, and is useful as a medicament for treating allergy by alleviating or minimizing airway inflammation of a subject.
... | | Allergy prevention method and system | 20090265381 | 20091022 | | An allergy prevention method and system. The method includes retrieving, by a computing system from a fidelity card, a user profile comprising information specifying first elements known to cause a user to have an allergic reaction. The computing system retrieves data associated with an item for purchase. The data comprises information specifying second elements comprised by the item. The computing system compares the first elements to the second elements to determine that a first element of the first elements matches a second element of the second elements. The computing system generates and presents to the user, a warning indicating that the first item may cause the user to have an allergic reaction.
... | | Seed koji for brewing, koji for brewing, brewed foods and method for producing the same | 20090258110 | 20091015 | | [PROBLEMS] To provide a seed koji for brewing, which is suitable for wheat allergy patients and wheat intolerance patients (patients with celiac disease) and the medium of which is completely free from wheat-origin component, a koji for brewing, brewed foods and a method of producing the same. [MEANS FOR SOLVING PROBLEMS] Whole soybeans are hulled. A koji mold belonging to the genus Aspergillus is inoculated into the soybean hull thus obtained and cultured therein to give a solid seed koji. By using this seed koji, brewed foods (for example, soy sauce, miso, a liquid seasoning and so on) free from wheat-origin component are produced. Thus, it is possible to obtain a seed koji which is free from wheat-origin component, shows a high sporulation rate of the... | | Blood and saliva test for detection of delayed food allergy and intolerance against modified foods | 20090253154 | 20091008 | | A method for determining the presence of delayed food allergy and intolerance against antigens extracted from modified foods. The method includes determining a level of antibodies against a modified dietary food antigen in blood and mucosal samples from the patient and comparing the level with normal levels of the antibodies. Dietary antigens that were tested include milk and modified milk products; eggs and modified egg products; meat and modified meat products; fish, mollusks, and crustaceans and their modified products; oils, fats and their modified products; grains and modified grain products; pulses, seeds kernels, nuts and their modified products; vegetables and modified vegetable products; fruits and modified fruit products; sugar, modified sugar products, modified chocolate products and confectionery; and spices and their modified forms.
... | | Blood and saliva test for detection of delayed food allergy and intolerance against modified foods | 20090253154 | 20091008 | | A method for determining the presence of delayed food allergy and intolerance against antigens extracted from modified foods. The method includes determining a level of antibodies against a modified dietary food antigen in blood and mucosal samples from the patient and comparing the level with normal levels of the antibodies. Dietary antigens that were tested include milk and modified milk products; eggs and modified egg products; meat and modified meat products; fish, mollusks, and crustaceans and their modified products; oils, fats and their modified products; grains and modified grain products; pulses, seeds kernels, nuts and their modified products; vegetables and modified vegetable products; fruits and modified fruit products; sugar, modified sugar products, modified chocolate products and confectionery; and spices and their modified forms.
... | | Anti-allergy compositions | 20090246287 | 20091001 | | The present invention relates to particles of glucans, particularly oxidized cellulosed for use in medicine. The invention further discloses pharmaceutical compositions for the treatment and/or prophylaxis of diseases or disorders associated with or mediated by allergens.
... | | Composition for improving membrane composition and functioning cells | 20080317868 | 20081225 | | the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.
... | | Herbal therapy for the treatment of food allergy | 20080317878 | 20081225 | | The present invention provides herbal formulas, and compositions thereof, that can treat or reduce the severity, intensity, or duration of food allergy and food allergyrelated symptoms. The compositions may optionally include one or more adjuvants, cytokines, encapsulating materials, or pharmaceutically acceptable carriers or excipients, and may be administered prior to, during, or after the development of food allergy-related symptoms in a patient in need thereof.
... | | N-acylic aminoacid derivatives, method for the production thereof, pharmacological composition and the use in the form anti-allergic, anti-inflammatory and hypolipidemic agents | 20080319040 | 20081225 | | or pharmaceutically acceptable salts thereof, to novel processes for preparing the same, to use thereof as anti-allergic, anti-anaphylactic, anti-inflammatory and hypolipidemic agents as well as to a pharmaceutical composition comprising the indicated compounds in an efficient amount and to a method for treating allergic and inflammatory diseases and lipid metabolism disorders: bronchial asthma, allergic rhinitis, pollinoses, seasonal and year-round rhinitis, allergic pneumonitis, atopic dermatitis, psoriasis, urticaria, allergic (including anaphylactic) reactions to insect stings and medicaments, cold allergy, allergic conjunctivitis, atherosclerosis, obesity, ischemic heart and cerebral disease, myocardial infarction and stroke.
... | | Functional food composition for treating allergy, natural tea using the same and the manufacturing method thereof | 20080311229 | 20081218 | | A functional food composition for treating allergy, comprising Saururus chinensis, Plantago asiatica, Poncirus trifoliata and Schisandra chinensis extracts, as active ingredients, a tea composition comprising the same and a manufacturing method thereof. The functional food and tea compositions for treatment of allergy in accordance with the present invention are therapeutically effective for any type of allergic diseases, irrespective of allergic causes. In particular, the tea composition advantageously enables easy and regular administration at need, which can achieve anti-allergic effects without particular efforts for treatment of diseases.
... | | Oxadiazole derivatives with crth2 receptor activity | 20080312220 | 20081218 | | Compounds of formula are CRTH2 ligands, useful for treatment of inflammatory, autoimmune, respiratory or allergy disease: wherein R1 is hydrogen or methyl and R2 is optionally substituted cycloalkyl, or optionally substituted non-aromatic heterocyclyl having to 6 ring atoms; or R1 and R2, taken together with the carbon atom to which they are attached form an optionally substituted cycloalkyl, or optionally substituted non-aromatic heterocyclyl having 4 to 6 ring atoms: or R1 and R2, taken together with the carbon atom to which they are attached form an optionally substituted cycloalkyl, or optionally substituted cycloalkyl, or optionally substituted non-aromatic heterocyclyl ring having 4 to 6 ring atoms; R is hydrogen or an optional substitutent by 1, 2 or 3 optional substituents; A is hydrogen or C1-C3 alkyl; and... | | Aminodiazepines as toll-like receptor modulators | 20080306050 | 20081211 | | Provided are compositions and methods useful for modulation signaling through the Toll-like receptor TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.
... | | Recombinant anti-interleukin-9 antibodies | 20080299134 | 20081204 | | The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.
... | | Quinoline derivatives as pi3 kinase inhibitors | 20080300239 | 20081204 | | Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.
... | | Composition for improving membrane composition and functioning of cells | 20080292649 | 20081127 | | c/ a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.
... | | Composition for improving membrane composition and functioning cells | 20080292724 | 20081127 | | the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.
... | | Quinoxaline derivatives as pi3 kinase inhibitors | 20080293706 | 20081127 | | Invented is a method of inhibiting the activity/function of PI3 kinases using quinoxaline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoxaline derivatives.
... | | Pharmaceutical composition and non dependence coffee comprising edible carboxylic acid and/or its acid salts and coffeine | 20080286388 | 20081120 | | Pharmaceutical composition and food comprising edible carboxylic acid and/or its acidic salt and optionally caffeine, crude drug and pharmaceutical acceptable carrier are disclosed. The invention also discloses the use and method of composition or food. The composition or food of the present invention can prevent, treat or relief allergy, ache, cold, viral infection, thrombus or clotting, inflammation, cancer, intoxication, memory decay, caffeine dependence. The invention also relates to feedstuff for animals.
... | | Formulation of antigen | 20080280320 | 20081113 | | The present invention regards methods and formulations for diagnosis, prevention and treatment of disease. More particularly, the present invention teaches methods and formulations for diagnosis, prevention and treatment with antigen in autoimmune disease, allergy, rejection of transplants and cancer. Examples illustrate how the methods of formulations of the invention may be used for diagnosis and amelioration of autoimmune diabetes in which the 65kd isotype of glutamic acid decarboxylase (GAD) is a major antigen.
... | | New phenylalanine derivatives | 20080280909 | 20081113 | | wherein R1 is a methyl group and R2 is a methoxy group.
... | | Pd-1, a receptor for b7-4, and uses therefor | 20080274490 | 20081106 | | Disclosed is a method for modulating an immune response by modulating signaling via PD-1. The immune response may be downregulated by increasing signaling via PD-1, or may be upregulated by decreasing signaling via PD-1. Agents which are useful for stimulating signaling via PD-1 to downregulate an immune response include an activating antibody that recognizes PD-1, a form of B7-4 that binds to an inhibitory receptor, and a small molecule that binds to PD-1. Agents which are useful for inhibiting signaling via PD-1 to upregulate an immune response include a blocking antibody that recognizes PD-1, a non-activating form of B7-4, an antibody that recognizes B7-4, and a soluble form of PD-1. Also disclosed is a method for modulating the interaction of B7-4 with an inhibitory receptor on... | | T-cell epitope peptides | 20080274972 | 20081106 | | The T-cell epitope site on a Japanese cypress (hinoki) pollen allergen molecule has been identified by stimulating a T-cell line established from a patient suffering from Japanese cypress pollen allergy with an overlap peptide covering the primary structure of the Japanese cypress pollen allergen. The peptide is useful in peptide-based immunotherapy for patients with spring tree pollinosis including patients with Japanese cypress pollinosis having cross reactivity with Japanese cypress pollen. The peptide is also useful for diagnosing spring tree pollinosis.
... | | Variants of group 1 allergens from poaceae having reduced allergenicity and maintained t-cell reactivity | 20080267985 | 20081030 | | The present invention relates to the preparation and use of variants of the group 1 allergens of the Poaceae (sweet grasses) which are characterised by reduced IgE reactivity compared with the known wild-type allergens and at the same time by substantially maintained reactivity with T-lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventive immunotherapy of grass pollen allergies.
... | | Minimally invasive allergy testing system | 20080269635 | 20081030 | | An allergy testing system includes encapsulated allergens, a microneedle array, and an activation system coupled to the microneedle array and the encapsulated allergens such that the encapsulated allergens are moved into contact with a subject as the microneedle array is moved from a resting position to a penetrating position. A method for determining a degree of reaction to one or more allergens by a patient in a minimally invasive manner is also disclosed. Penetration of one or more microneedles into a skin of the patient is caused. Each of the penetrations into the skin is exposed with an allergen from each of the one or more microneedles. One or more images are captured of each of the penetrations into the skin. Each of the captured images... | | Loyalty card based allergy warning program | 20080270262 | 20081030 | | The present application discloses systems and methods for managing nutritional information which in some embodiments comprises a database coupled to a central processor, a storage module configured to store in the database a plurality of records comprising loyalty card data for products purchased with a loyalty card and nutritional information for products available for purchase with the loyalty card, and a plurality of records relating to after sale product information. These systems and methods may further comprise a data processing module configured to compare products purchased with a loyalty card with the after sale product information, and determine if there are conflicts and an output module for transmitting results, wherein the central processor is configured to generate a report based upon the information found in the... | | Allergy suppressive agent | 20080262080 | 20081023 | | Namely, it is intended to provide an allergy suppressive agent comprising chrysin, more specifically speaking, a histamine release inhibitory agent comprising chrysin; a composition comprising chrysin that is a composition for treating a disease or condition relating to the production of IgE; a composition comprising chrysin that is a composition for treating a disease or condition relating to a high-affinity IgE receptor; and a composition comprising chrysin that is a composition for treating a disease or condition relating to the overproduction of IL-4. It is preferable that the allergy suppressive agent and histamine release inhibitory agent according to the present invention further comprise apigenin.
... | | Bio-co-cr-mo alloy with ion elution suppressed by structure control, and process for producing same | 20080251163 | 20081016 | | This invention provides a technique for rendering bio-toxicity such as allergy toxicity derived from Ni trace impurity, i.e., nickel toxicity, which is unavoidably present in a bio-Co—Cr—Mo alloy or an Ni-free stainless steel alloy unharmful, characterized in that an element selected from the group consisting of the group 4, 5 and 13 elements of the periodic table, particularly an element selected from the group consisting of the group 4 elements of the periodic table, is added to the alloy composition. The additive element is preferably an element selected from the group consisting of zirconium and titanium, more preferably zirconium.
... | | Homeopathic composition for alleviating allergy symptoms | 20080254071 | 20081016 | | The present invention is directed towards a homeopathically designed composition comprising effective amounts of Thussilago petasites (butterbur) and dilute amounts of Ambrosia artemisiifolia for the alleviation of symptoms of an allergy. According to various aspects, the present invention may further comprise combinations of Allium cepa, Echineacea angustifolia, Euphrasia officinalis (eyebright), Pulsatilla nigricans, Pothos foetidus, Ignatia amara (St Ignatius' bean), and Thuja occidentalis (Tree of Life) to synergistically and additionally alleviate the symptoms of an allergy.
... | | Human lung surfactant protein, sp-d, modulates eosinophil activation and survival and enhances phagocytosis of apoptotic bosinophils | 20080255043 | 20081016 | | The present invention provides the use of formulation with surfactant protein-D (SP-D) in the modulation of activity of human eosinophils derived from hypereosinophilic patients to an increased activation state and increased apoptosis. Accordingly the utility of the invention can be extended in human subjects in resolution of eosinophilic inflammations in related diseases and disorders like neuromuscular and respiratory diseases with eosinophilia other than airway-hyperresponsiveness, allergy and asthma, hypereosinophilic leukemias, hypereosinophilc syndromes (rare hematological diseases), skin diseases like eosinophilia-Myalgia syndrome, eosinophilic fascitis, capillary leak syndromes (IL-2), Churg-Strauss syndrome, toxic oil syndrome, parasitosis, etc., where a large number of stimulated eosinophils accumulate and release a series of growth factors, cytokines, chemokines, bioactive lipid mediators, toxic oxygen metabolites.
... | | Thiazolidinedione derivatives as pi3 kinase inhibitors | 20080255115 | 20081016 | | Invented is a method of inhibiting the activity/function of PI3 kinases using thiazolidinedione derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of thiazolidinedione derivatives.
... | | Hyaluronidase inhibitor containing poly-gamma-glutamic acid as an effective component | 20080247986 | 20081009 | | The present invention relates to a hyaluronidase inhibitor containing poly-gamma-glutamic acid (PGA) as an active ingredient, a composition for maintaining skin elasticity and a composition for improving allergy, wherein each of the compositions contains PGA as an active ingredient. The inventive compositions containing PGA are effective in maintaining skin moisturization and skin elasticity by effectively inhibiting the activity of hyaluronidase which is an enzyme that degrades hyaluronic acid present in the skin dermis. Also, the compositions can relieve allergic symptoms by inhibiting the permeability of inflammatory cells.
... | | Regulation of mink in thymocytes and t lymphocytes | 20080248054 | 20081009 | | The invention relates to compositions and methods used to assess and alter the expression and activity of MINK in cells of the immune system, particularly thymocytes and T lymphocytes. The methods and compositions are used in a variety of clinical applications including vaccination, treatment of cancer, infectious disease, allergy, and transplantation. Screening methods are provided to identify inhibitors of MINK and susceptibility to effects of under- or over-expression of MINK.
... | | Method for removing enzyme and method of base exchange or hydrolysis of phospholipid using the same | 20080248543 | 20081009 | | A method of removing an enzyme from a liquid enzyme reaction mixture used in a hydrolysis reaction or a base exchange reaction of a phospholipid is provided. The method includes the step of treating the liquid enzyme reaction mixture with a solvent mixture of water and an organic solvent, wherein the solvent mixture includes an inorganic metal salt, to remove the enzyme. Enzymes included in the reaction product can be easily removed without a treatment such as heating, and thus it becomes possible to easily produce various phospholipids that have a reduced risk of inducing an allergy, that retain a high quality and that have excellent storage stability.
... | | Methods and compositions for treating ige-mediated diseases | 20080241069 | 20081002 | | This invention provides recombinant peptides comprising a fragment of an IgE constant region, nucleotide molecules encoding same, recombinant vaccine vectors comprising same, and methods for inducing immune response and treating allergy, asthma and IgE mediated disease comprising same.
... | | Methods and compositions for modulating il-17f/il-17a biological activity | 20080241130 | 20081002 | | The invention provides a novel mouse IL-17F/IL-17A, and further provides uses of such mouse IL-17F/IL-17A in the characterization of the IL-17F/IL-17A heterodimer. The present invention is also related to polynucleotides and polypeptides of the IL-17F/IL-17A signaling pathway, and targeting of the IL-17F/IL-17A signaling pathway in methods of treating IL-17F/IL-17A-associated disorders. The invention thus provides methods of using isolated IL-17F/IL-17A heterodimer, e.g., in a mouse model of airway inflammation, and specific or selective IL-17F/IL-17A modulators (e.g., signaling agonists or signaling antagonists (e.g., specific or selective antagonistic antibodies, specific or selective antagonistic small molecules, etc.)). The invention also provides methods of screening for compounds capable of modulating IL-17F/IL-17A biological activity, e.g., IL-17F/IL-17A signaling antagonists (e.g., using the mouse model of airway inflammation), as well as methods of identifying... | | Sinus relief composition and method of producing the same | 20080241290 | 20081002 | | The present invention provides a sinus relief composition and a method of producing the composition comprising oleoresin capsicum containing capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, and homocapsaicin as active ingredients, vegetable glycerin, purified water, eucalyptol, rosemary extract, ascorbic acid, and sea salt for fully relieving and preventing chronic and occasional sinus, allergy, and headache symptoms, including pain, dryness, inflammation, congestion, and coughing.
... | | Pharmaceutical uses of staurosporine derivatives | 20070299049 | 20071227 | | This application relates to the use of staurosporines derivatives for the curative, palliative or prophylactic treatment of allergic rhinitis, allergic dermatitis, drug allergy or food allergy, angioedema, urticaria, sudden infant death syndrome, bronchopulmonary aspergillosis, multiple sclerosis, or mastocytosis; and to a method of treatment of warm-blooded animals in which a therapeutically effective dose of a compound of a Staurosporine Derivative is administered to a warm-blooded animal suffering from one of the diseases or conditions mentioned above.
... | | Verification of extracted data | 20070299651 | 20071227 | | Facts are extracted from speech and recorded in a document using codings. Each coding represents an extracted fact and includes a code and a datum. The code may represent a type of the extracted fact and the datum may represent a value of the extracted fact. The datum in a coding is rendered based on a specified feature of the coding. For example, the datum may be rendered as boldface text to indicate that the coding has been designated as an “allergy.” In this way, the specified feature of the coding (e.g., “allergy”-ness) is used to modify the manner in which the datum is rendered. A user inspects the rendering and provides, based on the rendering, an indication of whether the coding was accurately designated as... | | Automatic decision support | 20070299665 | 20071227 | | Speech is transcribed to produce a transcript. At least some of the text in the transcript is encoded as data. These codings may be verified for accuracy and corrected if inaccurate. The resulting transcript is provided to a decision support system to perform functions such as checking for drug-drug, drug-allergy, and drug-procedure interactions, and checking against clinical performance measures (such as recommended treatments). Alerts and other information output by the decision support system are associated with the transcript. The transcript and associated decision support output are provided to a physician to assist the physician in reviewing the transcript and in taking any appropriate action in response to the transcript.
... | | Method of detemining tropomyosin in chitosan | 20070292903 | 20071220 | | This invention provides a method capable of easily determining with high accuracy a protein in chitosan, said protein having a potential relevance to the development of an allergy, specifically tropomyosin and the content of the peptide. According to the method, tropomyosin is determined by immunoassay with the chitosan being in a state dissolved in an aqueous solution of an organic acid. The present invention also provides chitosan, which has a measurement value of the protein, specifically tropomyosin not higher than a predetermined value as measured by the determination method and is assessed to have only a low risk of inducing the allergy.
... | | Ephrin and eph receptor mediated immune modulation | 20070292904 | 20071220 | | Methods and compositions for immune modulation are described. The methods involve modulating an ephrin or Eph receptor which consequently modulates an immune response, in particular a T cell response, modulates immune adhesion cell, modulates chemotaxis and/or migration or modulates apoptosis. The method is useful in treating a variety of conditions, including autoimmune disease, allergy, graft versus host disease, transplant rejection and cancer.
... | | Percutaneous pharmaceutical preparation for external use containing nonsteroidal antiinflammatory analgesic | 20070280980 | 20071206 | | A percutaneous pharmaceutical preparation for external use containing a nonsteroidal antiinflammatory analgesic. It is effective in inhibiting, with higher certainty, the hypersensitivity to light attributable to the phototoxicity and photoallergy of nonsteroidal antiinflammatory analgesics. It can sufficiently produce the effects of the nonsteroidal antiinflammatory analgesic while preventing the pharmaceutical preparation from being altered with time by the incorporation of a dibenzoylmethane derivative as a UVA absorber. The percutaneous pharmaceutical preparation for external use comprises, as essential ingredients, a nonsteroidal antiinflammatory analgesic, a dibenzoylmethane derivative, and one or more members selected among polyhydric alcohol/fatty acid esters, higher fatty acid esters, and crotamiton.
... | | Antigen-containing microspheres for the treatment of allergies | 20070275079 | 20071129 | | Microspheres containing antigens for allergy therapy, the microspheres having a binding constant of 1×104 M−1 toward a specific carbohydrate residue of intestinal and/or nasal epithelial cells.
... | | Formulations decreasing particle exhalation | 20070270502 | 20071122 | | Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.
... | | Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor | 20070265204 | 20071115 | | This invention pertains to inhibitors of atrial natriuretic peptide receptor A (NPRA) function, such as small interfering RNA (siRNA), useful for reducing the inflammation associated with many human diseases, such as asthma, respiratory syncytial virus (RSV) infection, and cancers (such as melanoma, lung cancer, and/or ovarian cancer) by interfering with NPRA gene expression or otherwise reducing NPRA function within a subject; and methods for treating a subject suffering from, or at risk of developing, an inflammatory disease, respiratory allergy (such as allergic rhinitis and asthma), viral infection, and/or cancer by administering such NPRA inhibitors to the subject.
... | | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | 20070265278 | 20071115 | | wherein R, R2, R3, R4, R5, R6, R7 and n are as defined herein, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutically acceptable prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of the prodrug, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (XVI) in admixture with a pharmaceutically acceptable carrier, a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation,... | | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists | 20070265291 | 20071115 | | wherein Cy1, Cy2, L1, L2, and R1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic... | | Reagents for diagnosis and therapy of latex allergy and method for the preparation of the same | 20070253965 | 20071101 | | The present invention relates to reagents for diagnosis and/or therapy of latex allergy or fruit allergy and to a method for the preparation of the reagents.
... | | Methods and formulations for inhibiting naturally occurring phosphodiesterase | 20070248701 | 20071025 | | Methods and formulations for using Tahitian Noni juice for inhibiting naturally occurring phosphodiesterases (PDEs). The present invention relates to Tahitian Noni juice as a PDE inhibitor to increase body energy and reduce allergy and asthma reactions
... | | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor | 20070244126 | 20071018 | | Benzoimidazol-2-yl pyrimidines and pyrazines, pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritis.
... | | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists | 20070244131 | 20071018 | | wherein Cy1, Cy2, L1, L2, and R1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic... | | Indoles and benzoimidazoles as histamine h4 receptor modulators | 20070238771 | 20071011 | | Benzoimidazole and indole compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.
... | | Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor | 20070232616 | 20071004 | | Benzoimidazol-2-yl pyridines, pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritis.
... | | Small molecule toll-like receptor (tlr) antagonists | 20070232622 | 20071004 | | The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency.
... | | Recombinant 12-kda protein useful for the detection of respiratory allergies | 20070224608 | 20070927 | | The present invention discloses the detection of an important 12K-Da protein having cross-reactivity amongst different prevalent allergenic grasses and fungi can be useful for detection of respiratory allergies. Conventionally, the whole extracts that are used for diagnosis are unable to specifically detect the causative agents. In addition, they are also responsible for additional non-specific sensitivities in patients to other components present in the extract. If a single cross-reactive protein is available, it can replace large number of extracts used for detection of raised IgE levels in allergy by ELISA, immunoblotting and the likes. Further, number of pricks would be reduced and this would benefit both patient and clinicians. It is further realized that production of such a protein by recombinant methods can lead to its availability... | | Novel therapeutic target and diagnostic marker for asthma and related conditions | 20070212353 | 20070913 | | CD48, a surface-marker molecule present in eosinophils, is disclosed herein as a key molecule in allergic conditions, particularly in allergic airway inflammations like asthma, allergy and nasal polyposis. CD48 is thus presented as a target molecule in the treatment of said conditions. In addition, diagnostic methods, and a kit for the diagnosis of allergic inflammatory conditions are described, based on the detection of CD48 expression.
... | | Novel hyaluronan-binding proteins and encoding genes | 20070213255 | 20070913 | | The present invention relates to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP, novel members of the hyaluronan receptor family. The invention provides isolated nucleic acid molecules encoding human to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors. Full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors. Further provided are therapeutic methods for treating disease states including, but not limited to, proliferative conditions, metastasis, inflammation, ischemia, host defense dysfunction, immune surveillance dysfunction, arthritis,... | | Methods and reagents for decreasing clinical reaction to allergy | 20070213507 | 20070913 | | It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by masking the site with a compound that prevents IgE binding or by altering as little as a single amino acid within the protein, most typically a hydrophobic residue towards the center of the IgE-binding epitope, to eliminate IgE binding. The method allows the protein to be altered as minimally as possible, other than-within the IgE-binding sites, while retaining the ability of the protein to activate T cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity The examples... | | Early childhood infection with human herpes virus type 6 (hhv-6) as a protection against the development of ige sensitization, atopic disease and allergy in young children | 20070207169 | 20070906 | | The present invention discloses a use of human herpes virus 6 (HHV-6) or derivatives thereof, for the manufacture of a pharmaceutical composition intended to be administered during early childhood, for the prevention of IgE sensitization and allergy development in young children. Examples of viral compositions include, but are not limited to live human herpes virus 6 (HHV-6).
... | | Fused heterobicyclic kinase inhibitors | 20070208053 | 20070906 | | and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X5, X7, R1, and Q1 are defined herein, inhibit kinase enzymes and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer. The compounds are also useful in the treatment of inflammation, allergy, asthma, disease and conditions of the immune system, disease and conditions of the nervous system, cardiovascular diseases, disease and conditions of the eye, dermatological diseases, osteoporosis, diabetes, multiple sclerosis, and infections.
... | | Benzimidazole compounds for modulating ige and inhibiting cellular proliferation | 20070202133 | 20070830 | | The present invention is directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. This invention also relates to benzimidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents.
... | | Immunotherapy for food allergy by reduced and alkylated food allergens | 20070190069 | 20070816 | | The invention relates to a treatment of human individuals suffering from food allergy. The treatment involves a specifically modified food allergen and is based on immunotherapy. The modified allergen is derived from a dietary protein, preferably a tree nut protein and is modified by reduction and alkylation.
... | | Gram positive bacteria preparations for the treatment of disease comprising an immune dysregulation | 20070190076 | 20070816 | | Compositions comprising components prepared from Gram positive bacteria such as Gram positive facultative intra-cellular bacteria, for example mycobacteria, including extended freeze-dried killed Gram positive bacteria, their method of preparation and their use in humans and animals, for the prevention and/or the treatment of disorders comprising an immune dysregulation such as cancer, autoimmune diseases, allergy and tuberculosis.
... | | Treatment for asthma and allergy | 20070190567 | 20070816 | | Several genes are upregulated in the lung of asthma or allergy sufferers. Many of the genes up-regulated in asthma are involved in arginine metabolism in the lung. Moreover, a set of 291 signature genes was found that can be used to indicate a patient's predilection for developing asthma or the patient's degree of suffering. Also, a set of 59 signature genes were found that indicate a patient's predilection for developing allergies. Many of the up-regulated genes relating to asthma were from the arginine metabolic pathway. Other genes, such as ADAM8, SPRR2A and SPRR2B were also strongly up-regulated in asthma. Treatment of asthma may be accomplished by administering compositions which decrease the levels of Arginase I, Arginase II, CAT2, or other arginase pathway members in the lung.... | | Amino acid diamides in non alpha position which are useful as adjuvants for administration of biological active agents | 20070191302 | 20070816 | | Amino acid diamides in non α position of formula (1), wherein R1 is selected from amongst the group consisting of the functional groups alkyl, halogen, NO2, OH, OCH3 alone or associated and R2 is selected from the group consisting of functional groups H, alkyl, halogen, NO2, OH, OCH3, which are useful as adjuvants for the administration of biological active agents, as well as pharmaceutical compositions containing these diamides of formula (1) and the use thereof for the manufacture of antithrombotic medications and for the manufacture of a medication for the treatment of a disease selected from amongst the group consisting of inflammation, cancer and allergy.
... | | Methods and compositions for diagnosis and immunotherapy of pollen allergy | 20070183978 | 20070809 | | A diagnostic pollen array includes allergens extracted from pollen coat material and pollen cytoplasm. Diagnostic pollen arrays are useful to diagnose allergy in individuals, identify novel allergens, identify genetic loci responsible for allergy in hosts, and to develop personalized treatment plans for allergy.
... | | Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions | 20060287285 | 20061221 | | A method and composition for the treatment of hormone allergy is disclosed. The method relates to using progesterone dilutions, or any other steroid hormone, to treat the systemic symptoms of hormone allergy, including pain. The composition of the hormone dilutions ranges from 10−1 to 10−5. The hormone dilution may be administered sublingually, or, in the alternative, an intradermal route of administration may be chosen. Hormone dilutions may be administered at daily intervals or on any other treatment schedule as required to alleviate a patient's symptoms.
... | | Pre-delivery drug identification system | 20060287884 | 20061221 | | The present invention is a system and method of pre-delivery drug identification. The system and method is implemented where drugs are being administered, such as in a hospital or clinic, and identifies the drug being administered to the patient before the drug reaches the patient. After identification, the system and method is configured to cross-reference the identified drug with the patient's prescription and allergy information, and to prevent delivery to the patient, if necessary.
... | | Injected drug identification and fail-safe system | 20060287887 | 20061221 | | The present invention is a system and method of pre-delivery drug identification. The system and method is implemented where drugs are being administered, such as in a hospital or clinic, and identifies the drug being administered to the patient before the drug reaches the patient. The system and method may utilize a sensor used for other physiologic monitoring to identify the drug. After identification, the system and method is configured to cross-reference the identified drug with the patient's prescription and allergy information, and to prevent delivery to the patient, if necessary. The system and method also utilizes data collected from the patient with a physiological monitor or a ventilator sensor to further determine whether the drug is appropriate for the patient. The method and system may... | | Methods utilizing novel target genes related to immune-mediated diseases | 20060280684 | 20061214 | | The present invention provides methods utilizing novel target genes related to immune-mediated diseases, such as asthma, allergy and autoimmune diseases. The invention is based on a molecular level description of the polarization of CD4+ precursor cells (Thp) from which T helper cells are known to originate. Particularly, the present invention provides a method of identifying a compound capable of modulating the polarization of CD4+ lymphocytes. The invention is also related to a method for assessing the presence of, or a predisposition to, an immune-related disorder in a subject.
... | | Amines that inhibit a mammalian anandamide transporter, and methods of use thereof | 20060281742 | 20061214 | | One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to asthma, neuropathic pain, persistent pain, inflammatory pain, hyperactivity, hypertension, brain ischemia, Parkinson's disease, spasticity, Tourette's syndrome, schizophrenia, hemorrhagic shock, septic shock, cardiac shock, migrane, Horton's headache, multiple sclerosis, anorexia, AIDS wasting syndrome, organ rejection, autoimmune diseases, allergy, arthritis, Crohn's disease, malignant gliomas, neurodegenerative diseases, Huntington's chorea, glaucoma, nausea, anxiety, psychosis, attention deficit hyperactivity disorder, premature ejaculation, and stroke. Another aspect of the present invention relates to combinatorial libraries of... | | Antibodies that specifically bind to chemokine beta-4 | 20060275210 | 20061207 | | The present invention relates to antibodies and related molecules that specifically bind to CK-B4. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including cancers, as well as immune system diseases and disorders including autoimmune diseases, inflammatory disorders, immunodeficiencies, infections, HIV, arthritis, allergy, psoriasis, dermatitis, and inflammatory bowel disease. The invention also relates to nucleic acid molecules encoding anti-CK-B4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancers, as well as immune system diseases and disorders including autoimmune disease, inflammatory disorders, immunodeficiencies, infections, HIV, arthritis, allergy, psoriasis,... | | Molecule | 20060275312 | 20061207 | | We describe an Fve polypeptide being a fragment, homologue, variant or derivative of Fve protein, which comprises at least one biological activity of Fve protein. Uses of such a polypeptide, etc, and nucleic acids encoding these, in the treatment and prevention of allergy and cancer are also disclosed.
... | | Non-injection immunotherapy | 20060269576 | 20061130 | | Methods and compositions are disclosed for the reduction of immune responses to an exogenous allergen. The reduction is obtained by pre-treatment or pre-conditioning, without injection, of a subject with the allergen so as to reduce immune responses in the subject upon additional exposure to the allergen. The invention is advantageously used in a variety of contexts, including seasonal allergies wherein pre-treatment or pre-conditioning is performed before the onset of the seasonal allergy.
... | | Allergy inhibition | 20060269577 | 20061130 | | Allergen contact with a person's allergen-responsive tissues is reduced by removing airborne allergens from body surfaces adjacent the person's eyes. Airborne allergens may be removed from body surfaces adjacent the person's eyes by irrigating such areas with an irrigating fluid or by wiping such areas with a pad. Preferably the irrigating fluid or the pad is treated to augment its effectiveness in removing airborne allergens or otherwise preventing them from entering the eye, and/or to reduce allergy symptoms in the eye area caused by airborne allergens that enter the eye.
... | | Screening assay for tlr7, tlr8 and tlr9 agonists and antagonists | 20060269936 | 20061130 | | The present invention relates to novel screening methods for identifying agonists and antagonists of toll-like receptor (TLR) 7, TLR8 or TLR9. Methods are disclosed for identifying agonists and antagonists of TLR7, TLR8 or TLR9 using mutant TLR proteins containing deletions in one or more extracellular leucine rich regions (LRRs). Such agonists and antagonists have utility in the prevention, treatment and/or cure of various diseases and conditions, including cancer, virus infection, allergy, asthma, and chronic obstructive pulmonary disease (COPD).
... | | Methods for the treatment and prevention of inflammatory diseases | 20060270630 | 20061130 | | The invention includes processes mainly for the treatment of a inflammatory diseases, such as inflammatory bowel disease, arthritis, atherosclerosis, asthma, allergy, inflammatory kidney disease, circulatory shock, multiple sclerosis, chronic obstructive pulmonary disease, skin inflammation, periodontal disease, psoriasis and T cell-mediated diseases of immunity, including allergic encephalomyelitis, allergic neuritis, transplant allograft rejection, graft versus host disease, myocarditis, thyroiditis, nephritis, systemic lupus erthematosus, and insulin-dependent diabetes mellitus. The processes involve treating a patient with a pharmaceutical composition containing an active ingredient that inhibits the activity of sphingosine kinase.
... | | Materials and methods for inhibition of ige production | 20060257364 | 20061116 | | The subject invention concerns novel methods and materials for treating patients afflicted with allergic conditions, such as allergic rhinitis, atopic dermatitis, bronchial asthma and food allergy. The method of the subject invention comprises administering interferon tau (IFNτ) or a chimeric IFN (ovine IFNτ (1-27)/human IFNαD (28-166)) to a person afflicted with an allergic condition. When administered, IFNτ and chimeric IFN suppress the production of IgE antibodies without toxic side effects. The subject invention also concerns chimeric ovine/human IFNs which can be used in the methods of the invention.
... | | Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions | 20060257420 | 20061116 | | x is a direct bond or linker for covalently bonding P1 and P2.
... | | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | 20060258728 | 20061116 | | wherein R1 is —COOH, —COOR6, etc.; A is a single bond, alkylene, etc.; R2 is alkyl, alkoxy, etc.; B is a carbocyclic ring or a heterocyclic ring; Q is alkylnene-Cyc2, etc.; D is a linking chain; and R3 is alkyl, a carbocyclic ring or a heterocyclic ring, or a non-toxic salt thereof. The compound of formula (I) binds to PGE2 receptor, especially subtypes EP3 and/or EP4 and show the antagonizing activity, are useful for the prevention and/or treatment of diseases induced pain, itch, urticaria, allergy, urinary frequency, urinary disturbance, Alzheimer's disease, cancer, dysmenorrhea, endometriosis, etc.
... | | Deproteinized natural rubber, its composition and use thereof | 20060252879 | 20061109 | | There are provided natural rubber free from substances which cause Type I allergy, a rubber compositions having good processability and physical properties which comprises the natural rubber and other rubber, and a tire product comprising the natural rubber. The natural rubber of the present invention exhibits the above properties by containing substantially no proteins specified by the bands of 14, 31 and 45 kDa by SDS-PAGE.
... | | Tooth-borne radio-frequency medical read-write memory chip | 20060244569 | 20061102 | | A system and method for providing information about a user, where a wireless-transmitting read-write memory device for recording, storing and transmitting medical information is secured to a person's tooth. The medical Information comprises at least one of the user's past medical information; allergy Information, past surgical history Information, airway Issue information, anesthesia-related problem information, lab value information, baseline EKG information, physical examination Information, emergency contact information, insurance Information, date of birth, sex, height, weight and family history information.
... | | Clckb mutation as a diagnostic and therapeutical target | 20060240459 | 20061026 | | The present invention relates to a method for diagnosing hypertension, and/or allergy, and/or hair loss, and/or liabilty for infection, of a human being, or a predisposition therefor; to a nucleic acid molecule coding for a human ClCKb protein comprising a genetic alteration at amino acid position 481 compared to the wild type, as well as for corresponding segments thereof; to a nucleic acid molecule which binds to the before-mentioned nucleic acid molecule under stringent conditions, as well as to a nucleic acid molecule which binds to that nucleic acid molecule; to a (poly)peptide encoded by the afore-mentioned nucleic acid molecules; to a method for identifying substances modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to... | | Immunointeractive molecules and uses thereof | 20060233785 | 20061019 | | The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having latex allergy and genetic sequences encoding the same. These molecules are preferentially immunointeractive with T cells in subjects having a Hev b 6 allergy. The present invention also extends to antibodies, preferably monoclonal antibodies, directed to latex allergens and in particular to Hev b 6, and to the B cell epitopes recognized therein. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Hev b 6 or derivatives or homologues thereof.
... | | Inhibition of t cell activation by butyrophilin 4 or b7-l1 | 20060233819 | 20061019 | | The invention provides methods for modulating an immune response comprising contacting an immune cell with an agent that modulates BTF4 or B7-L1 mediated signaling. BTF4 or B7-L1 mediated signaling may either be increased, to thereby downregulate the immune response, or alternatively may be decreased, to upregulate the immune response. Modulation may be either activation or inhibition, and contacting may occur in vivo or in vitro. Performance of this method in vivo is also potentially therapeutic for an individual who may benefit from the upregulation or downregulation of an immune response. Such modulation to downregulate the immune response serves as a therapeutic e.g., for an individual who has received an organ transplant, or has a condition such as an allergy, or an autoimmune disorder. Alternatively, modulation to... | | Novel compounds | 20060233839 | 20061019 | | The present invention provides a novel treatment for allergy comprising the provision of a recombinant Der p 1/ProDer p 1/PreProDer p 1 allergen derivative, ProDer p 3 or a recombinant ProDer p 3/Der p 3/PreProDer p 3 allergen derivative with hypoallergenic activity. Pharmaceutical compositions comprising said mutant allergens which stimulate a Th1-type immune response in allergic or naïve individuals thereby reducing the potential for an allergic response upon contact with the wild-type allergen, are also provided.
... | | Functional domain and associated molecule of dock2 essentially required in lymphocyte migration | 20060234294 | 20061019 | | The present invention is related to provide a method for screening a substance interfering in the association of DOCK2 and ELMO1, a method for screening a substance interfering in the association of ELMO1 and Tiam1, and a method for searching a therapeutic agent for immune related diseases such as allergy, autoimmune diseases, GvH, graft rejection with the use of these searching methods, and so on. It was found that in DOCK2-mutant lacking 504 amino acid residues at the N terminus of DOCK2, Rac-activating ability was significantly decreased, and that actin polymerization could not be induced, and ELMO1 was identified as a molecule binding to this domain. It was found that DOCK2 was associated to ELMO1 via SH3 domain. Moreover, it was found that ELMO1 is bound... | | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | 20060235031 | 20061019 | | and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
... | | Hypoallergenic allergy vaccines based on the timothy grass pollen allergen phl p7 | 20060216314 | 20060928 | | The present invention pertains to polypeptides derived from the timothy grass pollen allergen Phi p 7. The polypeptides display reduced allergen activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination.
... | | Minor allergen control to increase safety of immunotherapy | 20060210590 | 20060921 | | The invention discloses a method for standardizing allergen extract with respect to the contents of major as well as minor allergens. The method comprises determining relative amounts of allergens in a given extract, followed by an adjustment of the contents of major an minor allergens so as to meet predefined limitations. Also disclosed is an anti-allergy kit comprising means for profiling an allergic subject and an extract or series of extracts prepared according to the invention.
... | | Class of medications is proposed, named rphx® | 20060212311 | 20060921 | | The invention is based on creating a new Class of medication to be a transitional class between Rx Medication and OTC Medication. The new Class is to be named RPhX, and is primarily authorized and dispensed by a pharmacist. As the patient requests an item in the RPhX class, a licensed pharmacist must perform drug review of the patient's medication to avoid drug allergy, Interaction etc. A pharmacist can write a prescription for this RPhX class. Certain information is needed including the Facility of Practice, Address, Telephone Number, Pharmacist name, License number, Signature, Medication name, Strength, and Amount, to be documented on the prescription. The new Class of Medication present an economical benefits by reducing the overall healthcare spending.
... | | Benzofuran compound and medicinal composition containing the same | 20060194851 | 20060831 | | wherein each symbol is as defined in the description, a pharmaceutically acceptable salt thereof and the like. The compound of the present invention has superior leukotriene inhibitory action, BLT2 competitive inhibitory action, BLT2 blocking action, action for the prophylaxis or treatment of allergy, action for the prophylaxis or treatment of asthma and action for the prophylaxis or treatment of inflammation, and is useful as an agent for the prophylaxis or treatment of diseases such as allergic disease, asthma, inflammation and the like, and other diseases.
... | | Composition comprising at least one alkanolamide to inhibit megration of langerhans cells and uses therof | 20060194881 | 20060831 | | The invention concerns a composition containing at least an alkanolamide, optionally combined with at least a compound such as a metalloprotease inhibitor, a PKC inhibitor, an anti-inflammatory agent, a soothing agent, an immunosuppressor, an ion chelating agent, an oxazolin, an oxazolidinone and a carbamic acid derivative. The invention also concerns the use of such a composition as medicine, in particular its use for preventing or treating skin pathologies of allergic and/or inflammatory and/or irritative origin or resulting from a danger signal. The invention further concerns a method for cosmetic treatment of sensitive, irritated, intolerant, allergy-prone, ageing skin and/or mucosa exhibiting skin barrier disorder, or exhibiting non-pathological immunologic imbalance, which consists in applying such a composition on the skin and/or mucosa.
... | | T-cell epitope peptides | 20060188446 | 20060824 | | The T-cell epitope site on a Japanese cypress (hinoki) pollen allergen molecule has been identified by stimulating a T-cell line established from a patient suffering from Japanese cypress pollen allergy with an overlap peptide covering the primary structure of the Japanese cypress pollen allergen. The peptide is useful in peptide-based immunotherapy for patients with spring tree pollinosis including patients with Japanese cypress pollinosis having cross reactivity with Japanese cypress pollen. The peptide is also useful for diagnosing spring tree pollinosis.
... | | Immunomodulating compositions, processes for their production and uses therefor | 20060182726 | 20060817 | | The present invention discloses compositions and methods for antigen-specific suppression of immune responses, including primed immune responses. In particular, the invention discloses antigen-presenting cells, especially dendritic cells, whose level and or functional activity of CD40, or its equivalent, is impaired, abrogated or otherwise reduced, and their use for treating and/or preventing unwanted or deleterious immune responses including those that manifest in autoimmune disease, allergy and transplant rejection.
... | | Allergy tester | 20060178615 | 20060810 | | The present invention relates to a device for delivering a medicament or a diagnostic agent to the skin or mucosa of an animal such as a human being, wherein a chamber filled with the medicament or the diagnostic agent is separate from the housing with a rod capable of transferring the medicament or the diagnostic agent to the animal. The chamber is connected to the housing with the rod before transfer of medicament or diagnostic agent. In particular the invention relates to a device for delivering allergens in allergy tests.
... |
Other Directories (alphabetical): , , , , , , , , , , , , , , , , , , , , -
###
This listing is a sample listing of patents related to Allergy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Allergy with additional patents listed. Browse our RSS directory or Search for other possible listings.
|
